Bacteria-based Cancer Therapy Achieves Tumor Eradication Without Immune Cells

A associated investigation squad led by Professor Eijiro Miyako of nan Japan Advanced Institute of Science and Technology (JAIST), successful collaboration pinch Daiichi Sankyo Co., Ltd. and University of Tsukuba, has developed a groundbreaking immune-independent bacterial crab therapy utilizing a caller microbial consortium called AUN.

Cancer immunotherapy originated successful 1868 erstwhile nan German expert Busch reported a lawsuit of a crab diligent who was intentionally infected pinch germs and subsequently cured. Since then, successful 1893, Dr. William Coley projected nan usage of germs for crab treatment, and immunotherapies person been evolving into modern treatments specified arsenic checkpoint inhibitors and CAR-T cells for complete 150 years. While powerful, these approaches fundamentally dangle connected immune cells—making them ineffective for galore crab patients pinch compromised immune systems owed to chemotherapy aliases radiotherapy.
The recently developed AUN therapy overturns this long-standing limitation. AUN is composed of 2 people occurring bacteria:

• Proteus mirabilis (A-gyo), a tumor-resident microbe
• Rhodopseudomonas palustris (UN-gyo), a photosynthetic bacterium

• Selective demolition of tumor vasculature and crab cells
• Structural translator of A-gyo (filamentation) triggered by tumor metabolites, enhancing its antitumor potency
• Functional optimization via intratumoral organization displacement — though nan first bacterial substance is A-gyo : UN-gyo ≈ 3:97, it dramatically shifts to 99:1 wrong nan tumor microenvironment
• Suppression of pathogenicity and minimization of broadside effects, including nan avoidance of CRS

Notably, UN-gyo functions arsenic a regulatory partner only erstwhile coexisting pinch A-gyo, helping to suppress nan pathogenicity of some strains while simultaneously enhancing their tumor-specific cytotoxicity. This "cooperation of labor" mirrors nan Japanese philosophical conception of "AUN"—perfect harmony betwixt opposites. It is this delicate and move interplay betwixt nan 2 bacterial type that unlocks nan singular antitumor efficacy—a feat antecedently unattainable done accepted therapies.

To accelerate nan societal implementation of this research, we are preparing to motorboat a startup and purpose to statesman objective tests wrong six years."

Professor Eijiro Miyako, lead writer of nan study

"A caller section successful bacteria-based crab therapy—pursued for complete 150 years—is yet beginning."
This revolutionary attack represents a paradigm displacement for immunocompromised crab patients. It offers a long-awaited therapeutic solution successful cases wherever accepted immunotherapies fail—ushering successful nan dawn of genuinely immune-independent crab treatment.

The investigation has been published online successful Nature Biomedical Engineering connected 5 August 2025.